Upfront Diagnostics
PrivateLast Round
Grant
Jul 1, 2026
Total Funding Raised
$3.9M
Company Overview
Upfront Diagnostics operates in Healthcare & Life Sciences and is based in Cambridge. Its latest recorded funding round was a Grant round in July 2026.
Upfront Diagnostics is a biotechnology company that develops rapid point-of-care diagnostic tests for stroke detection.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotechnology
Business Model
B2B
Customer Profile
Hardware Sales
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Upfront Diagnostics Comparables
Compare Upfront Diagnostics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| ABCDx | 88% | |
| Galaxy CCRO, Inc. | 78% | |
| Sense Neuro Diagnostics | 77% |
For institutional investors. Book with your work email.
Upfront Diagnostics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Jul 1, 2026 | ||||
| Grant | Jun 21, 2025 | ||||
| VC Round | May 12, 2025 | ||||
| Grant | Mar 17, 2025 | ||||
| Seed | Jun 27, 2023 | ||||
Grant | Jun 27, 2023 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Upfront Diagnostics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Cambridge Enterprise Ventures | VC Round |
| SBRI Healthcare | Seed, Grant, VC Round |
| Centre for Process Innovation | Grant |
| APEX Ventures | Seed |
| Stroke Association | Seed, Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 22, 2025
Attending the 17th World Stroke Congress in Barcelona, October 22-24, 2025.
- Oct 14, 2025
Launched LVOne, a rapid point-of-care blood test for stroke triage.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- partners_withSep 29, 2026
On May 27th '26, UpFront Diagnostics Ltd. and Vingmed AB announced a strategic partnership under which Vingmed AB will serve as the authorised distributor for LVOne across the Nordic region.
For institutional investors. Book with your work email.
Upfront Diagnostics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Upfront Diagnostics's valuation, stock price, and market status.
Is Upfront Diagnostics a public or private company?
Upfront Diagnostics is a private company.
What is the current stock price of Upfront Diagnostics?
Upfront Diagnostics is a private company, so its shares have no public market price. Caplight tracks Upfront Diagnostics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Upfront Diagnostics worth (valuation)?
Valuation information for Upfront Diagnostics is not publicly available.
Can I buy Upfront Diagnostics stock?
Upfront Diagnostics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Upfront Diagnostics's last funding round?
Upfront Diagnostics's most recent funding round was Grant on July 1, 2026.
Who are the main investors in Upfront Diagnostics?
Key investors in Upfront Diagnostics include Centre for Process Innovation, APEX Ventures.
Will Upfront Diagnostics IPO soon?
No public IPO plans have been announced for Upfront Diagnostics.
How can I track Upfront Diagnostics secondary market activity?
Caplight tracks bids, offers, and trades in Upfront Diagnostics's shares on secondary markets.